ライフサイエンスコーパス: surrogate marker

1 , 0.8% minor errors) using micafungin as the surrogate marker.

2 des and may eventually be considered as a T2 surrogate marker.

3 unohistochemistry could serve as a potential surrogate marker.

4 ng process in terms of histology and certain surrogate markers.

5 naling, suggesting the peptides may serve as surrogate markers.

6 ages, allowing potential definition of novel surrogate markers.

7 odel and compare its performance to existing surrogate markers.

8 d for future research that evaluates or uses surrogate markers.

9 e were seen for 1 of 23 participant-reported surrogate markers, 2 of 25 visual spatial tests, and 2 o

10 nd cytometric bead array, formed an in vitro surrogate marker and correlate of the in vivo host immun

11 cer undergoing radical resection is an early surrogate marker and correlate to oncologic outcomes.

12 he fatty liver index (FLI) is a non-invasive surrogate marker and predictor of NAFLD.

13 ession of eIF3I in HCC is oncogenic and is a surrogate marker and therapeutic target for treatment wi

14 cle, we examine the challenges of evaluating surrogate markers and describe the framework proposed in

15 Correlations between surrogate markers and SES-CD were tested with the Spearm

16 nsitivity troponin T (hs-TnT) can be used as surrogate markers and whether genetic variability in ger

17 However, these surrogate markers are not entirely reliable and combinat

18 Many surrogate markers are used, such as documenting evidence

19 The serum sensitivity of each surrogate-marker assay was reduced in animals treated wi

20 We present case studies of 2 well-accepted surrogate markers [blood pressure within sodium intake a

21 nd monitored their fate by X-Gal staining, a surrogate marker coexpressed with the K-Ras(G12V) oncopr

22 Conclusion: As a hybrid surrogate marker comprising MR parameters and the PET co

23 All surrogate markers correlated moderately with SES-CD on a

24 FC as a surrogate marker could be used to validate risk factors

25 a genome-wide level by using common promoter surrogate markers (e.g., histone modifications) and were

26 Surrogate markers (eg, resistive index) fail to quantify

27 uced intrapatient variability of Tac Cmin, a surrogate marker for 24-hour drug exposure (AUC0-24), ha

28 d the accuracy of discharge destination as a surrogate marker for 6-month mobility impairment in acut

29 )F-FDG PET/MR enterography index as a hybrid surrogate marker for active ileocolonic inflammation in

30 phasizes the potential for DTC analysis as a surrogate marker for adjuvant treatment effect in breast

31 terventions that reduced alert quantity as a surrogate marker for alert fatigue.

32 ential biomarker for tumor progression and a surrogate marker for allosteric RAF blockade.

33 interval that QT prolongation is an accepted surrogate marker for arrhythmia.

34 ystolic, and mean arterial blood pressure, a surrogate marker for arterial stiffness.

35 erebrospinal fluid (CSF) tau is an excellent surrogate marker for assessing neuropathological changes

36 samples with raised osmolality and copeptin (surrogate marker for AVP).

37 amples with raised osmolality or copeptin (a surrogate marker for AVP).

38 IgE reactivity to PHMB as surrogate marker for biguanide/hexamethylene reactivity

39 Early neuroimaging may provide a surrogate marker for brain development and outcome after

40 protein expression was tested as a potential surrogate marker for BRCA1/2 inactivation.

41 ells expressing both a caspase-3 sensor as a surrogate marker for caspase-3 activation and Renilla lu

42 ctivation and Renilla luciferase (Rluc) as a surrogate marker for cell viability were established and

43 ol/L), and total-to-ionized calcium ratio, a surrogate marker for citratemia, was unchanged.

44 o measuring myocardial flow reserve (MFR), a surrogate marker for coronary vascular health.

45 light chain (NF-L) could be a more practical surrogate marker for disease staging in amyotrophic late

46 ed that the retinal vasculature may act as a surrogate marker for diseased cerebral vessels.

47 tted from the emergency department acts as a surrogate marker for early aggressive care in the manage

48 y correlated with HER2 status, possibly as a surrogate marker for ER status and a predictor for tamox

49 bacterial clearance could serve as a timely surrogate marker for evaluating the appropriateness of a

50 1 collagen-targeted gadolinium-based probe (surrogate marker for extracellular matrix (ECM) remodeli

51 pecific gadolinium-based probe (0.2 mmol/kg, surrogate marker for extracellular matrix degradation).

52 matory functional test for Glut1 DS and as a surrogate marker for GLUT1 haploinsufficiency.

53 It has the potential to be used as a surrogate marker for GS and predict LNI.

54 p16 is used as a surrogate marker for HPV infection.

55 Although p16 may be used as a surrogate marker for HR-HPV status in other tissue sites

56 PtdCho-DHA may be useful as a surrogate marker for in vivo hepatic PEMT activity in hu

57 SARS-CoV-2 culture may be used as a surrogate marker for infectivity and inform de-isolation

58 n oxide-based probe (ferumoxytol, 4 mgFe/kg, surrogate marker for inflammatory activity) and an elast

59 ) remodeling) and an iron oxide-based probe (surrogate marker for inflammatory activity), in one imag

60 monitoring the C. elegans exometabolism as a surrogate marker for internal metabolic events.

61 a circulating fragment of SOGA, providing a surrogate marker for intracellular SOGA levels.

62 flow (RPF), and filtration fraction (FF) (a surrogate marker for intraglomerular pressure) were meas

63 Measurement of CFIMs may be a surrogate marker for IPMN progression and allow for the

64 Pro-substance P (ProSP) is a stable surrogate marker for labile substance P, which has pro-i

65 stion the validity of relapse frequency as a surrogate marker for late disability.

66 s the importance of MRD-negative status as a surrogate marker for longer PFS in clinical studies to a

67 a clinical sign of intestinal failure and a surrogate marker for markedly increased risk of mortalit

68 Because weight is a surrogate marker for metabolic demands, we looked at the

69 Metastasis size serves as a surrogate marker for metastatic activity of colorectal l

70 nce relative to linear RNAs can be used as a surrogate marker for mRNA stability in the absence of tr

71 minant antiemetic used at GMH, was used as a surrogate marker for nausea in the initial GMH cohort; n

72 kers led to tumor mutational burden (TMB) as surrogate marker for neoantigens presented.

73 well as decreased levels of activated p65, a surrogate marker for NF-kappaB activity.

74 Since the catatonic syndrome is likely a surrogate marker for other executive function defects, w

75 recent metaanalysis could validate pCR as a surrogate marker for patient outcomes only in aggressive

76 we propose initial steroid sensitivity as a surrogate marker for post-transplant recurrence.

77 on, these data implicate Pin1 as a potential surrogate marker for predicting outcome of ERalpha-posit

78 Peritransplant ALC is a novel and useful surrogate marker for prediction of HCV recurrence and pa

79 lidate a specific amount of weight loss as a surrogate marker for protection.

80 h using endogenously generated VOCs can be a surrogate marker for recognition of sputum inflammatory

81 A wide pulse pressure may serve as a surrogate marker for risk following PCI and represents a

82 believe that FC is likely to prove a useful surrogate marker for risk of developing CD.

83 study aimed to evaluate vWF-Ag as an adjunct surrogate marker for risk stratification on the waiting

84 eptomeningeal enhancement may prove a useful surrogate marker for such pathology, perhaps improving o

85 pressed higher levels of cell surface CD5, a surrogate marker for TCR avidity for self-pMHC, as compa

86 itude of muscle contractions, representing a surrogate marker for the characteristic loss of muscle s

87 ggest that [F-18]-AV-1451 holds promise as a surrogate marker for the detection of brain tau patholog

88 t the degree of hypointensity can serve as a surrogate marker for the efficacy of tumor vaccination.

89 5-HTP uptake and retention in pancreas, as a surrogate marker for the endogenous islet mass.

90 11)C]5-HTP retention is a useful noninvasive surrogate marker for the human endocrine pancreas.

91 Blood albumin leakage could be a surrogate marker for the in vivo evaluation of intervent

92 olute lymphocyte count (ALC) is considered a surrogate marker for the level of immunosuppression and

93 an fluorescence intensity was not a suitable surrogate marker for the prediction of complement bindin

94 Micafungin may serve as an acceptable surrogate marker for the prediction of susceptibility an

95 evel of total alpha-synuclein could act as a surrogate marker for the progression of PD.

96 eperfusion treatment but rather represents a surrogate marker for the severity of risk and injury to

97 guidelines recommend trough monitoring as a surrogate marker for the target area under the curve ove

98 hinococcosis (AE) and has been proposed as a surrogate marker for therapeutic decisions on structured

99 ribosomal protein S6 (P-S6) was defined as a surrogate marker for TOR-dependent anabolic activity in

100 salpinx in women and mice has been used as a surrogate marker for tubal infertility, the medical rele

101 FDG PET could be used as a noninvasive surrogate marker for tumor growth and viability in this

102 S100A9 could serve as a surrogate marker for tumor immune crosstalk as a functio

103 ival within chicken (HD-11) macrophages as a surrogate marker for virulence.

104 While brain volume changes are used as surrogate markers for Alzheimer disease neuropathology i

105 thrombosis, despite the lack of evidence of surrogate markers for atherosclerosis in primary APS.

106 and CRISP2 DMRs hold promise as novel blood surrogate markers for early risk stratification and CVD

107 O-a free radical gas-has been difficult, and surrogate markers for eNOS activation are widely utilize

108 binding MR contrast agent and may be used as surrogate markers for evaluating the healing response of

109 The availability of surrogate markers for functional vascular proteins, such

110 and interleukin-6 (IL-6) levels were used as surrogate markers for inflammation and were measured at

111 iomarkers and determine their suitability as surrogate markers for interventional trials.

112 ereas serum levels of phytosterols represent surrogate markers for intestinal cholesterol absorption,

113 r arterial blood gas monitoring, noninvasive surrogate markers for lung disease severity are needed t

114 pulation of patients with asthma and provide surrogate markers for neutrophilic asthma.

115 T KO mice, RhBG expression was not affected, surrogate markers for oxidative stress were strongly up-

116 retina is an attractive source of potential surrogate markers for paediatric cerebral malaria becaus

117 id inflammatory markers (CFIMs), as possible surrogate markers for parenchymal inflammation.

118 vity fecal toxin detection rather than using surrogate markers for prediction.

119 magnitude of EBVd were assessed as potential surrogate markers for the occurrence of late adverse eve

120 verity markers, which use SpO2, are adequate surrogate markers for those that use PaO2 in children wi

121 al progenitor cell (EPC) counts are proposed surrogate markers for vascular function and cardiovascul

122 r potential usefulness in the development of surrogate markers for vector delivery during the first w

123 Improvement in surrogate markers has not necessarily translated into be

124 lity may not be a feasible endpoint and many surrogate markers have been explored, ranging from pulmo

125 Although surrogate markers have been identified and compelling CS

126 Preliminary studies that analyzed surrogate markers have suggested that operating room (OR

127 status of the optic nerve and will provide a surrogate marker in future remyelination clinical trials

128 lcitonin (PCT) has been shown to be a useful surrogate marker in identifying patients with various ba

129 At present, the suitability of CIMT as a surrogate marker in trials of cardiovascular therapies t

130 says and breath tests could become important surrogate markers in early bactericidal activity (EBA) s

131 research and the use of network measures as surrogate markers in research setting.

132 s an alternative or together with HbA1c as a surrogate marker indicator for glycemic control.

133 The correlation of PD with ASVD outcomes and surrogate markers is discussed, as well as the correlati

134 ve model with the use of different vitamin D surrogate markers (latitude of residence, mean annual re

135 The use of robust surrogate markers may accelerate early-phase drug develo

136 Furthermore, the use of surrogate markers may misrepresent the MAIT cell populat

137 Surrogate markers may provide insight into pathogenesis

138 arms, ICR (compared with CR) seemed to be a surrogate marker of a greater burden of anatomical coron

139 The latter may be a surrogate marker of abnormal heart rate variability in C

140 CCA test, which we consider to be a suitable surrogate marker of active infection.

141 -2, highlighting the potential of VLA-4 as a surrogate marker of acute lung inflammation.

142 Moreover, sputum EPX was a surrogate marker of airway eosinophilia in other patient

143 noninvasive imaging technique that detects a surrogate marker of apoptosis may help characterize the

144 show increased concentrations of copeptin, a surrogate marker of arginine vasopressin (AVP), to be as

145 ter of >/=40 from month 13 to month 25) as a surrogate marker of asymptomatic infection in the vaccin

146 easing peptide (pro-GRP) was identified as a surrogate marker of Bcl-2 amplification and changes corr

147 or partially the IGFBP and vWC domains as a surrogate marker of CCN1 activity in PDR distinguishing

148 significantly correlated with 2-week Ki67, a surrogate marker of clinical outcome (r = -0.179; P = .0

149 onounced coronary artery calcification, as a surrogate marker of coronary atherosclerosis, does not u

150 t measure of subclinical atherosclerosis and surrogate marker of coronary heart disease.

151 ilure strongly reduce midazolam clearance, a surrogate marker of CYP3A-mediated drug metabolism, in c

152 c magnetic resonance have been shown to be a surrogate marker of diffuse myocardial fibrosis.

153 rophy on serial MRI are frequently used as a surrogate marker of disease progression in Alzheimer's d

154 s that the PBMC transcriptome may serve as a surrogate marker of DOX-induced cardiotoxicity.

155 CD30 may be a surrogate marker of early replication or viral transcrip

156 n selecting patients and when using MRI as a surrogate marker of efficacy.

157 hosterol-to-cholesterol ratio (L:C ratio), a surrogate marker of endogenous cholesterol synthesis, se

158 Microparticles (MPs) have emerged as a surrogate marker of endothelial dysfunction and cardiova

159 endothelium-dependent vasodilation and is a surrogate marker of endothelial function and NO bioavail

160 a valid, reliable, repeatable, and specific surrogate marker of eosinophils and/or eosinophil degran

161 tion and fatty liver index (FLI; a validated surrogate marker of fatty liver), as well as the associa

162 alactomannan assay (GM), a non-culture-based surrogate marker of fungal infection, is widely used in

163 ed low pepsinogen 1 to 2 (PEP1:2) ratio as a surrogate marker of gastric atrophy.

164 miR-129-2 methylation in non-IM may be a surrogate marker of GC in H. pylori-infected patients.

165 her whole retinal thickness can be used as a surrogate marker of glaucomatous change.

166 ve shown that the SNR test provides a useful surrogate marker of hearing.

167 ft ventricular ejection fraction (LVEF) is a surrogate marker of heart failure (HF) status and associ

168 nsferase-to-platelet ratio index (APRI) as a surrogate marker of hepatic fibrosis to characterize liv

169 perioperative aspartate aminotransferase, a surrogate marker of hepatic ischemia reperfusion injury,

170 P16 overexpression, a surrogate marker of HPV association, was a strong predic

171 Expression of p16 is used as a surrogate marker of HPV infection.

172 gher residual SYNTAX Score was shown to be a surrogate marker of increasing clinical comorbidity and

173 RBC aggregation is a surrogate marker of inflammation that can be quantified

174 ole retinal thickness in the rat as a useful surrogate marker of inner and outer retinal changes.

175 elationship between body mass index (BMI), a surrogate marker of insulin resistance, and iron burden

176 We analyzed urinary dd-cfDNA as a surrogate marker of kidney transplant injury.

177 Allergen-specific IgG, which served as a surrogate marker of maintaining protective IgG responses

178 DC) at low- and medium-b-value regimens as a surrogate marker of microcirculation, to study its corre

179 d antibody-in-lymphocyte supernatant (ALS, a surrogate marker of mucosal immune responses) from patie

180 Measurement of a surrogate marker of neuronal activation (i.e., Arc mRNA)

181 ons, making this neuroinflammation process a surrogate marker of neuronal dysfunction.

182 elin-specific CD4 T cells expressing CD56, a surrogate marker of NK cells, were shown to be cytotoxic

183 P-43-related disease, and which is used as a surrogate marker of non-amyloid-beta protein aggregation

184 Although p16 protein expression, a surrogate marker of oncogenic human papillomavirus (HPV)

185 tracerebral haemorrhage, and may be a useful surrogate marker of ongoing ischaemic injury from small-

186 gm is lacking, the use of this paradigm as a surrogate marker of outcome is limited.

187 tes that the expression of p53R172H can be a surrogate marker of p53 gene transcription.

188 om arterial plasma to tissues) was used as a surrogate marker of perfusion to correct the binding pot

189 er(916), a modification frequently used as a surrogate marker of PKD1 activity.

190 llular volume fraction (ECV), representing a surrogate marker of reactive interstitial fibrosis, and

191 d related cancers, using FLT-PET as an early surrogate marker of response.

192 n-binding contrast agent, gadofosveset, is a surrogate marker of rupture-prone atherosclerotic plaque

193 apid noninvasive technique, may be used as a surrogate marker of SFN.

194 an indicator of diastolic dysfunction and a surrogate marker of significant left to right shunts.

195 ce is a crude explanatory variable that is a surrogate marker of socioeconomic status, education, and

196 (ADSCs) undergoing apoptosis can serve as a surrogate marker of stem cell death.

197 -67, indicative of cell division, and CD5, a surrogate marker of TCR avidity, and produced the cytoki

198 t that early metabolic response can act as a surrogate marker of the benefit of antiangiogenic therap

199 Circulating CLA(+) T cells may be a reliable surrogate marker of the inflammatory events occurring in

200 ein-Barr virus (EBV) DNAemia (EBVd) may be a surrogate marker of the net state of immunosuppression a

201 IP-10 thus may be a surrogate marker of the rate of intracellular viral repl

202 ot only a signpost of cholestasis but also a surrogate marker of the severity of primary biliary cirr

203 Using SOD2 as a surrogate marker of the UPR(mt), we found that in primar

204 released by these cells may be a measurable surrogate marker of this progression.

205 f allergen immunotherapy and may be a useful surrogate marker of treatment efficacy in future studies

206 igh-avidity Melan-A-specific clonotypes as a surrogate marker of treatment efficacy.

207 orrelation with PSA levels (P < 0.0001) as a surrogate marker of tumor burden, whereas SUVmax (P = 0.

208 colony-forming unit osteoblasts (CFU-Os), a surrogate marker of undifferentiated mesenchymal cells a

209 DRIL is a robust and easily obtained surrogate marker of VA in participants with current or r

210 correlated with fetal copeptin production, a surrogate marker of vasopressin, and dependent on the ex

211 HCMV IgG level, a surrogate marker of viral activity, was correlated with

212 Circumpapillary RNFL is a surrogate marker of vision and could be helpful in makin

213 yer (RNFL) thickness have been proposed as a surrogate marker of vision but this technique is also li

214 ith vision testing, HH-OCT measures may be a surrogate marker of vision.

215 were used to validate salivary VZV DNA as a surrogate marker of VZV reactivation and then to determi

216 to be associated with T1 relaxation times, a surrogate marker of water content, but not with GABAA re

217 ions to the public social security system, a surrogate marker of work rehabilitation.

218 3S/C33S) mice as determined from analyses of surrogate markers of active TGF-beta, such as P-Smad2, C

219 The search for valid surrogate markers of arterial vascular inflammation led

220 afor uptake is significantly associated with surrogate markers of atherosclerosis and is linked to th

221 tween serum micronutrient concentrations and surrogate markers of atherosclerosis in a cohort of HIV-

222 though quantified decoy cells are acceptable surrogate markers of BK viral replication with unexcepti

223 DED and ePiB, respectively) were compared as surrogate markers of brain perfusion, and the extent to

224 t on cIMT and little or no effect on several surrogate markers of cardiovascular disease in non-diabe

225 Recent evidence has shown that surrogate markers of cardiovascular risk, including symp

226 ation of atherogenic risk factors, including surrogate markers of carotid and coronary atherosclerosi

227 of drug candidates but also hold promise as surrogate markers of central neuroinflammation.

228 es, such as alpha/delta frequency ratio, are surrogate markers of cerebral ischemia.

229 Measurements of serum surrogate markers of cholesterol absorption (plant stero

230 In cholesterol stone group, surrogate markers of cholesterol synthesis in serum (e.g

231 Surrogate markers of cholesterol synthesis in serum (squ

232 Using expression of optimal surrogate markers of co-stimulation/exhaustion signature

233 Therefore, Vbeta expansions can serve as surrogate markers of CTL clonality to assess clonal kine

234 ls from uninfected animals, but importantly, surrogate markers of cytotoxicity in infected macaques w

235 rocirculatory perfusion status, as direct or surrogate markers of disease, are therefore of uttermost

236 ected imprinted genes may therefore serve as surrogate markers of DNA methylation in cancer tissue.

237 in view of the absence of easily measurable surrogate markers of efficacy.

238 rculating endothelial cells (CECs) represent surrogate markers of endothelial damage.

239 Purpose To quantify surrogate markers of endothelial function in nonsmokers

240 ajor limitation of this study was the use of surrogate markers of frailty and comorbid conditions to

241 Studies examining surrogate markers of genetic susceptibility to AF, such

242 tion led by renal dietitians did not improve surrogate markers of glucose metabolism.

243 o-ethyl)-l-tyrosine ((18)F-FET) were used as surrogate markers of glucose utilization, proliferative

244 dothelial cell therapy showed mean levels of surrogate markers of hepatobiliary injury that were cons

245 Given their utility as surrogate markers of HIV disease progression, this sugge

246 We hypothesized that surrogate markers of host immune response may predict su

247 EBVd within the first 6 months after SOT are surrogate markers of increased risk of IRAE.

248 l studies that assessed associations between surrogate markers of innate technical abilities in surgi

249 indications for empirical treatment based on surrogate markers of invasive candidiasis are warranted.

250 contact force, ablation duration, and these surrogate markers of lesion formation may allow us to de

251 TE is one of the best current surrogate markers of liver fibrosis in PBC.

252 chanistic link between fetal environment and surrogate markers of long-term health.

253 yocardial carbonic anhydrase 9 and collagen, surrogate markers of myocardial hypoxia.

254 s have tended to use biochemical and imaging surrogate markers of NAFLD, such as elevated gamma gluta

255 disease (sCJD) are based on the detection of surrogate markers of neuronal damage such as CSF 14-3-3,

256 cortex showed that JNK inhibition suppressed surrogate markers of neurovascular remodeling, including

257 Many proteins have been proposed to act as surrogate markers of organ damage, yet for many candidat

258 iopoietin-2 release correlated strongly with surrogate markers of organ dysfunction and disease sever

259 artially independent of insulin resistance), surrogate markers of oxidative stress and gut microbial

260 ed a significant increase in lesion size and surrogate markers of plaque vulnerability.

261 es of trials of aggressive statin therapy on surrogate markers of progression have shown no benefit f

262 e factor 6 (KLF6) as critical regulators and surrogate markers of prostatic tissue architectures, whi

263 transcriptome data may be useful in defining surrogate markers of protection and pathology, they shou

264 tive tuberculosis (aTB) may help to identify surrogate markers of protection, as LTBI subjects are mo

265 ighlight the limitations of current in vitro surrogate markers of protection, such as cell-based neut

266 to women of all ancestries; 2) intermediate surrogate markers of response to preventive measures; 3)

267 ly that these 2 structural parameters may be surrogate markers of retinal function in the early stage

268 unological and transcriptional signatures as surrogate markers of successful immunotherapy.

269 Therefore, surrogate markers of T cell activation such as CD69, CD4

270 Assessment of surrogate markers of TdP-risk, such as QT-interval prolo

271 ign of embolic protection devices focuses on surrogate markers of the clinical disease, primarily on

272 e (LPR) and exploratory immune monitoring as surrogate markers of therapeutic response.

273 There is a critical need for real time surrogate markers of therapeutic success, to aid in pati

274 tigen (PCNA) and FANCD2 monoubiquitinations (surrogate markers of TLS and FA pathway activation, resp

275 (RNAi)-mediated suppression of ENOX1 impairs surrogate markers of tumor angiogenesis/vasculogenesis,

276 The assessment of surrogate markers of tumor progression in circulating ex

277 Screening programs using surrogate markers of viral replication are important pre

278 Gene expression of the WNT-pathway surrogate marker osteopontin and the metastasis-associat

279 ondary adjuvant treatment and the subsequent surrogate marker potential of DTCs for outcome determina

280 en FSR, suggesting applications as direct or surrogate markers, respectively, of hepatic fibrogenesis

281 genes in the peripheral blood can be used as surrogate marker(s) for DOX-induced cardiotoxicity.

282 e of the improved CSF RT-QuIC is superior to surrogate marker tests for prion diseases such as 14-3-3

283 The aim of this study was to identify surrogate markers that distinguish between systemic infl

284 hosphoinositide cycle and has CNS effects on surrogate markers that may be relevant to the treatment

285 score which uses biopsy transcriptomics as a surrogate marker to accurately track disease severity.

286 erefore, MRD quantification might serve as a surrogate marker to assess treatment efficacy in randomi

287 high frequency oscillations can be used as a surrogate marker to distinguish the core seizure territo

288 erase chain reaction can be used as a timely surrogate marker to evaluate the appropriateness of anti

289 reated a GFP knockin mouse and used GFP as a surrogate marker to examine C5aR expression.

290 Using CD103 as a surrogate marker to identify cells that have undergone T

291 ction of such substitutions would serve as a surrogate marker to identify resistant isolates.

292 cCEST MRI signal can be used as a label-free surrogate marker to non-invasively assess mucin glycosyl

293 Anidulafungin can accurately serve as a surrogate marker to predict S and R of Candida to caspof

294 ressed the application of anidulafungin as a surrogate marker to predict the susceptibility of Candid

295 ues, we evaluated the use of micafungin as a surrogate marker to predict the susceptibility of Candid

296 t in childhood, there is a critical need for surrogate markers to best assess, predict, and treat the

297 or monitoring disease progression and act as surrogate markers to identify underlying disease process

298 ver-operating-characteristic curves for each surrogate marker were created and tested against each ot

299 Very few surrogate markers were found to predict technical perfor

300 r the identification of treatment-associated surrogate markers, which may be provided by neuroimaging